SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to a newly announced multi-year joint research agreement with Honda, which validates the company's solid-state battery technology through rigorous benchmarking. The community is actively debating the significance of this OEM partnership, weighing the technical validation against the long-term timeline for commercial production.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending due to its pivotal role as a primary power infrastructure provider for AI data centers, with community sentiment fueled by major contract wins and ongoing hyperscaler demand. While the stock has seen explosive long-term growth, investors are actively debating its current valuation levels and the volatility associated with its rapid ascent in the energy space.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is surging as investors pivot to its new AI infrastructure identity, fueled by the formal completion of its Northern Data acquisition and the launch of the 'Quake AI' division. The community is buzzing over the massive influx of GPU capacity and potential cloud contracts, creating high conviction among bulls regarding a massive short squeeze and long-term valuation re-rate.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining significant momentum as investors digest recent positive clinical milestones and anticipate the upcoming start of the Phase 3 lung cancer trial, which serves as a key validator for the company's manufacturing progress. Community discussions are heavily focused on the potential for a large-scale M&A event or partnership, with many interpreting the current accumulation by institutional holders as a sign of high-conviction value ahead of the company's late-stage pipeline milestones.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense downward pressure and widespread community skepticism as investors debate the sustainability of its debt-fueled Bitcoin accumulation strategy and the potential for systemic risk. The stock is a focal point for intense conflict between those calling for a structural collapse and those viewing the current volatility as a generational buying opportunity.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing high volatility and retail interest driven by its position in the post-quantum cybersecurity sector, fueled by speculative short squeeze narratives and active discussion of its low float. The community remains polarized, with some traders targeting technical breakouts and accumulation, while others express concerns over fundamental performance and the firm's history of heavy dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention as investors anticipate a major shift in institutional demand driven by the upcoming Russell Index reconstitution, which necessitates mandatory buying from passive funds. The community is actively tracking potential catalysts, including regulatory updates and revenue performance, while discussing how these factors might counteract persistent short-selling pressure.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is rallying as investors react to strong quarterly growth, a transformative shift toward a semiconductor-based business model, and a high-profile partnership with Midjourney. While the community is debating potential future share offerings and the long-term competitive landscape, bullish sentiment remains centered on the company's proprietary chip technology and aggressive expansion into point-of-care AI imaging.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is gaining significant traction as traders focus on its low float and strategic backing from major players like IonQ and Dell, positioning it as a potential "picks and shovels" play in the quantum software sector. While sentiment is divided between those anticipating a rapid short squeeze and skeptics raising concerns about limited patents and long-term valuation, the community is actively debating its potential as a specialized software-layer firm compared to other hardware-focused companies.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are trending as investors weigh an upcoming FDA advisory committee meeting for its mRNA flu vaccine against the company's broader efforts to expand its pipeline in oncology and rare diseases. The community remains sharply divided, with bulls pointing to long-term pipeline potential and clinical progress, while bears continue to scrutinize the company's path to profitability and recent regulatory hurdles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush Initiates Coverage of Sionna Therapeutics (SION)

Wedbush Initiates Coverage of Sionna Therapeutics (SION...

Sionna Therapeutics (NASDAQ:SION) Upgraded to "Strong-Buy" at Wedbush

Wedbush raised Sionna Therapeutics to a "strong-buy" rating in a report on Monday...

Sionna Therapeutics, Inc. $SION Shares Acquired by Jennison Associates LLC

Jennison Associates LLC increased its stake in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) by 11.8% in the fourth quarter, according to its most recent 13F filing with the Securities...

JonesTrading Forecasts Strong Price Appreciation for Sionna Therapeutics (NASDAQ:SION) Stock

JonesTrading boosted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a "buy" rating in a research report on Tuesday...

Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch

Key PointsA director of Sionna Therapeutics reported the sale of 55,345 shares for a total transaction value of $2.47 million, using a weighted average price of $44.67 per share across April 17-18, 2026...

Sionna Therapeutics (NASDAQ:SION) Earns "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and set a $58.00 price target on shares of Sionna Therapeutics in a report on Monday...

Sionna Therapeutics (NASDAQ:SION) Stock Price Up 6.7% - Here's What Happened

Sionna Therapeutics (NASDAQ:SION) Stock Price Up 6.7% - Still a Buy...

Sionna Therapeutics (NASDAQ:SION) Stock Price Down 11.3% - What's Next?

Sionna Therapeutics (NASDAQ:SION) Shares Down 11.3% - Here's What Happened...

Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 52,397 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 52,397 shares of the firm's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $44.68, for a total value of $2,341,097.96. Following the transaction, the director...

Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 52,397 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Peter Thompson sold 52,397 shares of Sionna Therapeutics stock in a transaction on Friday, April 17th. The shares were sold at an...

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Sionna Therapeutics Inc.

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$37.25
Prev Close	$36.73
Open	$37.75
Dividend Yield	0.00%
50-Day Moving Average	$39.90
Beta	1.06
Avg. Volume	380,887.02
PE Ratio	-19.16

52-Week High	$48.45
52-Week Low	$13.81
Market Capitalization	$1.66B
EPS (Annual)	-$1.68
Price to Book	5.74
Revenue Per Employee	$0.00

SIONSionna Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SION News